REGN Profile
Regeneron Pharmaceuticals, Inc. is a leading biopharmaceutical company that focuses on discovering, inventing, developing, manufacturing, and commercializing medicines to treat a variety of diseases globally. Among its key products is EYLEA, an injection used to treat conditions such as neovascular age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma, and retinopathy of prematurity. The company also offers Dupixent, an injection for the treatment of atopic dermatitis and asthma in both adults and pediatric patients, as well as Libtayo, an injection for treating metastatic or locally advanced cutaneous squamous cell carcinoma.
Regeneron’s diverse portfolio extends to products like Praluent, an injjection for managing heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults, and REGEN-COV, a treatment developed for COVID-19. Kevzara, a solution for treating rheumatoid arthritis in adults, and Inmazeb, an injection for infections caused by the Zaire ebolavirus, are also part of its offerings. Additionally, the company provides ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome, and ZALTRAP, an injection for intravenous infusion to treat metastatic colorectal cancer. Beyond these, Regeneron is developing a range of product candidates targeting eye diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious and rare diseases, cancer, pain, and hematologic conditions.
Regeneron’s collaborative efforts are extensive, involving partnerships and license agreements with notable entities such as Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. The company also collaborates with the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., Biomedical Advanced Research Development Authority, and AstraZeneca PLC. Founded in 1988, Regeneron Pharmaceuticals is headquartered in Tarrytown, New York, and continues to be at the forefront of biopharmaceutical innovation and patient care.
|
